ABT vs AJG Stock Comparison

Scores Breakdown

Metric	ABT	AJG
📈 Growth	18/30	22/30
💰 Profitability	17/20	19/20
🏦 Financial Health	18/20	15/20
💵 Valuation	12/20	12/20
⚠️ Risk (lower is better)	4/10	4/10
Overall Score	71/100	74/100

Metric

ABT

AJG

📈 Growth

18/30

22/30

💰 Profitability

17/20

19/20

🏦 Financial Health

18/20

15/20

💵 Valuation

12/20

⚠️ Risk (lower is better)

4/10

Overall Score

71/100

74/100

Side-by-Side Summaries

ABT Analysis	AJG Analysis
📈 Growth & Financial Trajectory Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B. 💰 Margins & Cash Flow Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter. Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B). 🛡️ Balance Sheet & Liquidity Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow. ⚠️ Key Drivers & Risks Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management. Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.	📈 Growth & Financial Trajectory From Q3 2024 to Q2 2026 AJG grew revenue from $2.8068B to $4.003B (+~42%), while net income to parent rose from $314.1M to $324.0M (+~3%). The trend shows a strong top‑line expansion with earnings generally steady in later quarters. 💰 Margins & Cash Flow Operating margins remained high, averaging about 82%, with a dip in Q1 2025; margins remain robust. Cash flow was positive from operating activities in most quarters (e.g., $10M in Q2 2026) with investing outflows offset by financing activity, supporting solid cash generation. 🛡️ Balance Sheet & Liquidity Total assets near $81.8B and liabilities around $58.1B in Q2 2026, with equity ~$23.7B. Current ratio near 1.05x, noncurrent liabilities around $14.9B. Leverage is moderate and liquidity resilient. ⚠️ Key Drivers & Risks Drivers: Stable insurance brokerage demand and diversified client base; potential uplift from operational leverage. Risks: Earnings volatility across quarters; sensitivity to macro/regulatory cycles and valuation sensitivity due to leverage.

ABT Analysis

AJG Analysis

📈 Growth & Financial Trajectory

Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B.

💰 Margins & Cash Flow

Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter.
Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B).

🛡️ Balance Sheet & Liquidity

Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow.

⚠️ Key Drivers & Risks

Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management.
Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.

📈 Growth & Financial Trajectory

From Q3 2024 to Q2 2026 AJG grew revenue from $2.8068B to $4.003B (+~42%), while net income to parent rose from $314.1M to $324.0M (+~3%). The trend shows a strong top‑line expansion with earnings generally steady in later quarters.

💰 Margins & Cash Flow

Operating margins remained high, averaging about 82%, with a dip in Q1 2025; margins remain robust. Cash flow was positive from operating activities in most quarters (e.g., $10M in Q2 2026) with investing outflows offset by financing activity, supporting solid cash generation.

🛡️ Balance Sheet & Liquidity

Total assets near $81.8B and liabilities around $58.1B in Q2 2026, with equity ~$23.7B. Current ratio near 1.05x, noncurrent liabilities around $14.9B. Leverage is moderate and liquidity resilient.

⚠️ Key Drivers & Risks

Drivers: Stable insurance brokerage demand and diversified client base; potential uplift from operational leverage.
Risks: Earnings volatility across quarters; sensitivity to macro/regulatory cycles and valuation sensitivity due to leverage.

ABT vs AJG Stock Comparison

Scores Breakdown

Side-by-Side Summaries

📈 Growth & Financial Trajectory

💰 Margins & Cash Flow

🛡️ Balance Sheet & Liquidity

⚠️ Key Drivers & Risks

📈 Growth & Financial Trajectory

💰 Margins & Cash Flow

🛡️ Balance Sheet & Liquidity

⚠️ Key Drivers & Risks

Similar Companies

Top Rated Companies